Bausch Health Companies (BHC) Gross Margin (2009 - 2026)
Bausch Health Companies' (BHC) quarterly Gross Margin came in at 73.6% in Q2 2026, up 316.0% year-over-year from 17.69% in Q2 2025, and up 3.03% quarter-over-quarter from 71.43% in Q1 2026.
Analysis
Bausch Health Companies (BHC) Gross Margin (2009 - 2026) Analysis & Trends
Bausch Health Companies has disclosed Gross Margin across 18 years of filings, most recently posting 73.6% for Q2 2026.
- In Q2 2026, Gross Margin rose 316.0% year-over-year to 73.6%; the TTM figure through Jun 2026 stood at 72.43% (up 108.0% YoY), while the FY2025 annual figure was 71.27%, down 37.0% from the prior year.
- Gross Margin came in at 73.6% for Q2 2026 at Bausch Health Companies, up from 71.43% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 73.6% in Q2 2026 to a low of 69.77% in Q1 2025.
- Average Gross Margin over 5 years is 71.51%, with a median of 71.29% recorded in 2026.
- Year-over-year, Gross Margin sank 148 bps in 2023 and surged 316 bps in 2026.
- Over 5 years, Gross Margin stood at 70.86% in 2022, then gained by 0 bps to 71.14% in 2023, then gained by 2 bps to 72.22% in 2024, then fell by 0 bps to 72.0% in 2025, then rose by 2 bps to 73.6% in 2026.
- Per Business Quant data, the three most recent Gross Margin figures were 73.6% in Q2 2026, 71.43% in Q1 2026, and 72.0% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 51.98% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 38.77% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 46.52% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 42.01% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 73.60% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 4.68% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 62.35% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 50.83% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 95.97% |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 73.60% |
| Mar 31, 2026 | 71.43% |
| Dec 31, 2025 | 72.00% |
| Sep 30, 2025 | 72.58% |
| Jun 30, 2025 | 70.43% |
| Mar 31, 2025 | 69.77% |
| Dec 31, 2024 | 72.22% |
| Sep 30, 2024 | 72.83% |
| Jun 30, 2024 | 70.54% |
| Mar 31, 2024 | 70.83% |
| Dec 31, 2023 | 71.14% |
| Sep 30, 2023 | 72.65% |
| Jun 30, 2023 | 70.47% |
| Mar 31, 2023 | 70.58% |
| Dec 31, 2022 | 70.86% |
| Sep 30, 2022 | 71.99% |
| Jun 30, 2022 | 71.12% |
| Mar 31, 2022 | 72.05% |
| Dec 31, 2021 | 72.31% |
| Sep 30, 2021 | 72.81% |